Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
NBC is taking the office back from Netflix as it seeks to bolster its own streaming service launching in 2020.Technologyread more
Wayfair employees plan to walk out tomorrow, after no action was taken in response to their opposition to the company supplying border detention camps with beds for children.Retailread more
Micron beat analyst estimates on earnings and revenue for its fiscal third quarter of 2019.Technologyread more
Omarosa Manigault Newman, who had been a senior advisor to President Donald Trump before her firing, was sued for allegedly failing to file required financial disclosures.Politicsread more
San Francisco on Tuesday became the first city in the country to ban e-cigarettes after city officials voted in favor of an ordinance that prohibits the sale of any...Health and Scienceread more
See which stocks are posting big moves after the bell on June 25.Market Insiderread more
Citron Research's Andrew left reiterated his bet against the Canadian cannabis industry Wendesday, telling CNBC that he's short Canopy Growth and Cronos Group in addition to his already disclosed wager against Tilray.
Fielding a question from "Halftime Report " host Scott Wapner, Left said his doubts on the space aren't confined to just one company.
"I'm also short Cronos, I'm short Canopy, I'm short Tilray. So I'm short a basket of the names," he said. "Once the U.S. licensed producers come on — the faster it becomes legal in the U.S., the quicker the Canada names go lower."
"They won't get the exposure in the U.S., they're not players internationally," Left added. "I don't care how many press releases they put out, they're not going to be shipping cannabis from Canada to Australia. Not happening."
Shares of the three Canada-based marijuana producers sank Wednesday between Left's comments and Canopy Growth's earnings results. Tilray shed 11 percent and Canopy fell 15 percent in the U.S., while Cronos dropped 5.4 percent in Toronto.
Left's midday remarks came hours after Canopy Growth's second-quarter revenues results missed even the most conservative Wall Street estimate.
The company's total revenue of 23.3 million Canadian dollars fell well short of the average analyst expectation of CA$60 million despite growing 33 percent from the prior year's second quarter. The results represent Canopy's first sequential top-line decline.
To be sure, only a few analysts cover Canopy, a fact that makes any consensus projection less precise.
"With business opportunities expanding globally, we continue to make significant investments in building our international team and footprint," Bruce Linton, Canopy's chairman and co-CEO, said in a press release. "The completion of, to our knowledge, a world first Canadian export of a U.S. federally legal DEA permitted product, and the announced acquisition of U.S. federally legal hemp R&D specialists, ebbu, are critical stepping stones for our broader entrance into the U.S. market."
Of the few analysts that cover Canopy, Canaccord Genuity's Matt Bottomley said he's not too concerned that Canopy's second-quarter results suggest disappointments going forward. He maintained his buy rating on shares following the earnings release.
The weaker revenue is "a hiccup in getting products to Germany, along with minimal initial shipments into provincial recreational channels," he wrote to clients. "We believe we will see higher recreational sales impacting the company's top line next quarter. Given the company's leading position with 70,000 kilograms in supply agreements (excl. Ontario), we believe this could amount to more than $300 million in revenues and can support the company's leading position in the recreational market."
Canopy has been seen as a better bet in the cannabis space thanks to a $5 billion strategic partnership from international brewer Constellation Brands. Access to capital is seen by some analysts as key to the future success of marijuana companies, which are struggling to build up enough production to meet swelling demand.
"We think Constellation Brand's recent investment provides significant additional financial capacity and operational capabilities to become a leading CPG company, longer-term," Cowen analyst Vivien Azer wrote Monday, before the earnings results. "We think that demand for Canopy's products remains strong. As we have highlighted in our e-commerce platform checks, Canopy has steadily grown its product listings amongst our five province sample, covering 65 percent of Canada's population."
Azer had forecast Canopy posting revenue of CA$60 million.
Neither Canopy nor Tilray reported a significant bump in sales thanks to recreational cannabis. However, this is likely unrepresentative because Canada's prohibition against adult recreational use was overturned at the start of the third quarter, on Oct. 17.